# A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

> **NCT07347938** · — · NOT_YET_RECRUITING · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 6000 (estimated)

## Conditions studied

- Tetanus

## Interventions

- **DRUG:** Siltartoxatug Injection
- **DRUG:** HTIG/TAT/F(ab')₂

## Key facts

- **NCT ID:** NCT07347938
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 6000 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347938, "A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07347938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*